key: cord-0035375-3rzidc6x authors: Ensser, Armin title: Vector-based antiviral therapy date: 2006 journal: New Concepts of Antiviral Therapy DOI: 10.1007/978-0-387-31047-3_19 sha: 7b941d75d7feda1c9eaac41ef1c9bfe1a5833ae8 doc_id: 35375 cord_uid: 3rzidc6x nan It is only by Beelzebul, the prince of demons, that this man casts out demons. Matth. 12:24 The feasibility of therapeutic gene transfer is widely accepted for cancer and genetic disease, and two thirds of human clinical trials were as yet performed in cancer patients. Herpesviruses, lentiviruses, papillomaviruses and hepatitis B and C viruses (HBV, HCV) all cause significant burden of disease in man. They establish persistent infections that are in many aspects similar to genetic disease or cancer, and several viruses are in fact cancerogenic. Similar attempts as in cancer gene therapy have thus been applied to viral infections, while the success of vaccination against infectious disease has on the other hand prompted studies to vaccinate against cancer. The majority of studies in humans that use gene transfer in infectious disease (about 7% of more than 1000 trials world wide) are HIV-related (68 of 72 registered trials on infectious disease, as of June 2005) ; the few others are on immunotherapy directed against Cytomegalovirus (CMV), Epstein Barr virus (EBV) and HCV (The Journal of Gene Medicine Clinical Trial Site, 2005; Office of Biotechnological Activities at NIH and the Recombinant DNA Advisory Committee, 2005) . The ingenuity of researchers has come up with an abundance of antiviral targeting strategies, including promising recent developments such as RNA interference, strategies to specifically direct an antiviral immune response toward infected cells, and vaccination procedures that involve gene-modified antigen presenting cells. Many techniques are still in a preclinical or conceptual stage. The major hurdle of most vectorbased approaches remains the delivery of the therapeutic principle to the transfer will more than likely remain an absolute exception in the foreseeable future, the viral foe will usually have a head start; in addition, for reasons of biosafety, the carefully controlled therapeutic vector has a fundamental disadvantage versus the spread of the infectious agent which is not hindered by such considerations. "It'll be great to have polymers if they work, but I don't think they're ficient enough yet -viruses have learned to do this over millions of years" (Inder Verma, in: Clayton, 2004) This review will focus on potential treatments that involve transfer of a plasmid or viral vector based expression cassette as the therapeutic principle. Some of the approaches discussed here are also being developed for direct short term treatment, such as synthetic nucleic acids and proteins. The final goal of efficient and selective transduction of target cells with a therapeutic vector in the patient in vivo is not in sight. Current transfer sytems lack sufficient target cell selectivity, although various attempts are being made to adapt existing vector systems (Tab. 1). These include pseudotyping retro-or lentiviral particles, modifying retroviral envelope proteins (Sandrin et al., 2003; Verhoeyen and Cosset, 2004) , construction of tropism-modified adenoviruses (Mizuguchi and Hayakawa, 2004) or Adeno-associated virus (AAV) vectors (Buning et al., 2003) , or integration of modified glycoproteins into herpesviruses (reviewed in Grandi et al., 2004) . (virus-infected) target cell. Since preemptive application of antiviral gene ef 2.1 Integrating viral vectors "With AAV and retrovirus vectors you're just rolling the dice" (William M. Pardridge, in: Clayton, 2004) The successful correction of X-linked severe combined immunodeficiency (SCID-X1) in young children by retroviral transfer of the cytokine receptor common gamma chain (γc) (Hacein-Bey-Abina et al., 2002) had been greeted enthusiastically as the fulfillment of the promises gene therapy had not been able to keep for more than a decade. It was soon followed by a tragic setback when three children developed treatment-associated T-cell leukemia that was associated with LMO2 gene expression, very likely the consequence of insertional activation by the retroviral vector (Hacein-Bey-Abina et al., 2003; Kaiser, 2005) . Insertion mutagenesis is the most significant problem of the otherwise convenient and widely used integrating vectors (Baum et al., 2003) . Retroviral insertion mutagenesis had been observed previously in animal models; rhesus monkey infected by a retroviral vector contaminated with replication competent retrovirus developed T-cell leukemia (Donahue et al., 1992) , and (EIAV) based lentiviral vector (Themis et al., 2005) . Why have those side effects not been observed before? It has been estimated that in the French trial the number of retroviral insertion events exceeded those of all previous studies together. High vector dose, usage of a conventional vector with complete LTR, and the growth stimulatory properties of the transduced γc gene, plus increased viability and engraftment of gene-modified cells may in summary have precipitated the occurrence of side effects. Compared to the prognosis of SCID-X1 patients in which matched related donors are unavail-Dose-finding will be important, as is development/application of newer generations of retro-and lentiviral vectors that will improve the outcome. These are self-inactivating (SIN) due to deletion of the enhancer elements in the LTR U3 region and can therefore avoid the direct activation of genes in the vicinity of the integration site. Nevertheless, dose-dependent genotoxicity by insertional gene inactivation is likely associated with any integrating viral vector. Safety concern might be overcome by including suicide genes that allow ablation of vector-transduced cells. advance in the treatment of this severe disease (Baum et al., 2004) . patients of the French and related gene therapy trials represent a significant able, however, the current survival rates and outcome in the remaining reported for the first time for a non-primate equine infectious anemia virus allowed for longer observation times (Li et al., 2002b) . It was recently retroviral mutagenesis was later also recognized in murine models that However, expression of prodrug-activating genes can cause undesired elimination of transduced cells when the suicide gene is recognized by the immune system (Riddell et al., 1996) . Furthermore, in the context of a transformation and replication competent rhadinoviral vector, the Herpes simplex virus thymidine kinase (HSV-TK) gene unexpectedly enhanced viral pathogenicity in primates (Hiller et al., 2000a) , despite having been able to eliminate transduced cells in vitro (Hiller et al., 2000b) . Dependoviruses and Adeno-associated virus (AAV) vectors have not been commonly associated with side effects from integration (Bell et al., 2005) , although tumors have been observed after AAV-transduction in mice (Donsante et al., 2001) . Site specific integration of AAV-vectors at chromosome 19q13, which was previously considered the theoretical basis for longterm AAV gene transfer, is now recognized to be a rather infrequent event. Although it occurs at the high multiplicities of infection in nature, it requires approximately 100 to 1000 infectious particles per target cell after transduction with AAV vectors (Duan et al., 1998; Schnepp et al., 2003; Nakai et al., 2001) . Reports by the Kay group provided insights into the nature of rAAV2 vector integration into chromosomes in quiescent somatic cells in animals and human subjects (Nakai et al., 2003) , describing the host chromosomal effects of rAAV2 integration in mice. This result was greeted with mixed enthusiasm (Kohn and Gänsbacher, 2003) , but complemented earlier data from tissue culture (Miller et al., 2002 ). An extended analysis of AAVintegration sites in mice confirmed that AAV has the potential to act as an insertional mutagen (Nakai et al., 2005; Miller et al., 2005) , although it does not seem to induce chromosome breaks by itself (Miller et al., 2004) . Episomal persistence and replication in the infected cell is a shared characteristic of the Herpesvirus and Polyomavirus life cycle, though integration occurs and is associated with significant pathology in humans (cervical/genital/skin cancer by human papillomaviruses) or chicken (Marek's Disease Herpesvirus, MDV). EBV integration has been occasionally described in cultured cell lines but is considered a rare event in vivo (Gulley et al., 1992; Delecluse et al., 1993) . Herpesviruses other than MDV do not regularly integrate and possess a number of attractive features such as large packaging capacity, a mechanism for active replication and segregation of the viral episome, a broad host range, and infection of non-dividing cells. This encouraged the development of a number of episomally persisting vectors based on Herpes simplex virus (HSV), CMV, EBV and the animal Herpesvirus saimiri (Cotter and Robertson, 1999; Mazda, 2002; Conese et al., 2004; Oehmig et al., 2004; Doody et al., 2005; Wieser et al., 2005) . Vectors build on RNA-virus replicons such as Alphavirus lack the capability for long-term persistence. Since they elicit a strong immune response, they will possibly find an application in immunotherapy and vaccination studies, where only transient expression is required and their immune stimulating properties may be advantageous. Recombinant or DNA-based vaccines hitherto have not made their way into advanced clinical testing, nor are recombinant viral vector-based vaccines licensed in Europe or the US. Nevertheless, transfer of naked DNA into skin or muscle has been successfully applied for DNA-vaccination studies in animals, also in combination with booster strategies that involve viral expression vectors ; this has been able to provide protection from Filovirus challenge, and similar to adenoviral vector expressed Ebola virus glycoprotein alone rapidly protects primates (Sullivan et al., 2003) . Encapsulated forms of DNA have been delivered successfully in vivo to the liver or joints; transfer using cationic or receptor targeted liposomes is nonetheless inefficient, as the vehicle is frequently cleared from the circulation by phagocytic cells before the target is reached. Ex vivo transfer of DNA by lipids or electroporation, also in a flow-through format, may be possible and a practicable way of nonviral gene transfer (summarized in Rössig and Brenner, 2004) . There are basically two lines of attack, (A) directed against the exogenous target such as RNA-virus genomes and viral transcripts and, (B) to interfere with transcripts of host cell cofactors that are important for the invasion, replication, or pathogenicity. DNA or RNA-targeting drugs have the advantage that by their sequencespecific action they are much easier to design compared to drugs that need to interact with structured targets such as cellular or viral proteins (Tab. 4.3.2). Multiple sequence targets can be combined in one formulation, although efficiency might be decreased by saturation, e.g. of RNA-interference (RNAi) pathways. The initial assumption that the non-proteinaceous nature of nucleic acid-based drugs prevents host immune response that would otherwise limits efficacy, did not hold true. Innate immunity is also activated via Toll-like receptors (TLR) that recognize CpG motifs and dsRNA, resulting in stimulation of the interferon system. The most important barrier for all nucleic acid-based treatments is their intrinsic low capacity to cross the cellular membrane, as they must be delivered into the inside of the cell. Before they can arrive there in sufficient amounts, they must remain stable and should have no toxicity in the host. Ribozymes have not been approved for clinical use so far, and the only licensed antisense DNA drug (Fomivirsen, which is directed against human CMV for treatment of retinitis) is not a great commercial success due to more reliable alternative treatments. After delivery across the cell membrane, the drug has to be released e.g. from the endosome and find its way to its target, which has to be structurally accessible. Compared to short-lived transfer of synthetic molecules, it seems therefore more attractive to perform vector-mediated transfer of expression cassettes for enzymatically active ribozymes, decoy molecules and specifically for siRNA-precursors (below), which also use physiological cellular mechanisms for transport and processing. Cellular micro-RNAs (miRNAs) are an ancient physiological mechanism for posttranscriptional gene silencing (PTGS). PTGS by miRNA or RNAinterference (RNAi) is a common eukaryotic defense pathway conserved all the way from plants over fungi to animals. It was first noted more than a decade ago in plants, then fungi, nematodes, flies and higher animals. The underlying molecular mechanism of miRNA and RNAi are highly similar and have been elucidated mostly by the work of Tuschl and colleagues (Tuschl et al., 1999; Zamore et al., 2000; Elbashir et al., 2001a Elbashir et al., , 2001b . Briefly, RNA polymerase II transcribes mammalian miRNA genes into long primary miRNAs (pri-miRNAs), which are then processed in the nucleus into 70-80-nucleotide hairpin-like precursor miRNAs (pre-miRNAs) by Drosha, a nuclear RNAse III which is in complex with DGCR8, an RNA binding protein. Exportin-5 together with its cofactor Ran-GTP transport pre-miRNAs to the cytoplasm, where they are processed by the RNAse III Dicer into mature 22-nucleotide duplex miRNAs. The Dicer containing complex processes long double-stranded RNA precursors into the small interfering RNAs (siRNAs) that mediate RNAi. Beginning at the dufuture mature miRNA (also called guide RNA). Unwound mature miRNAs are plex end with the lower thermodynamic stability, miRNA duplexes are unwound, and the miRNA strand that has its 5' terminus at this end is the then incorporated into a miRNA ribonucleoprotein complex analogous to the RNA-induced silencing complex (RISC). The miRNA/RISC then downregulate the target by translational inhibition or target mRNA cleavage. This is determined by the degree of complementarity between the miRNA and target gene, in combination with Argonaute proteins, which are present in RISC. All Argonaute proteins can bind miRNAs and siRNAs, and Argo-naute2 (eIF2C2) is the catalytic component of the RISC that mediates targeted RNA cleavage. Near-perfect complementarity results in cleavage, followed by general RNA degradation of the targets, while partial complementarity causes translational inhibition, though the exact mechanism for translational inhibition is not known. Translational inhibition seems more common than miRNA-directed cleavage in animals (reviewed in Wienholds and Plasterk, 2005 ; see also Chapter 1.3, Figure 5 ). Given that the recognition of miRNA usually involves 1-2 mismatches to its target sequence, current bioinformatic prediction methods for miRNA and their potential targets are not dependable, and detection of miRNAs, their targets, and validation of target specificity so far mostly rely on experimentation. As indicated, PTGS by RNAi is a conserved mechanism of antiviral defense, all the way from plants to animals This is indicated by the finding that several viruses have evolved proteins interfering with RNAi. Viral secondary defense mechanisms targeting these viral proteins (Li et al., 1999; Savenkov and Valkonen, 2002) . Likewise, suppression of RNA interference by animal viral pathogens was recently described (Li et al., 2002a; Lichner et al., 2003; Bucher et al., 2004; Delgadillo et al., 2004; Li et al., 2004; Soldan et al., 2005) . Interestingly, it was recently found that some viruses, mostly largegenome DNA-viruses, have evolved or acquired expression of miRNAs (Pfeffer et al., 2004 (Pfeffer et al., , 2005 Samols et al., 2005; Cai et al., 2005) . A first viral miRNA function has been revealed in that the simian polyomavirus 40 encoded miRNA regulates large T antigen expression and reduces susceptibility of infected cells against cytolysis by cytotoxic T-cells (Sullivan et al., 2005) . The cellular or viral targets of other virus encoded miRNAs are unknown. Roth et al., 2004) , and plants in response seem to have evolved suppressors of PTGS were first recognized in plants (reviewed in Voinnet "RNAi is what antisense never was. It's robust and reproducible, and it exists in nature" (Inder Verma, in: Clayton, 2004) Within a few years, the technique of RNAi has been widely and successfully employed in the dissection of cellular and viral functions, and the enormous potential for therapeutic application has been rapidly recognized (reviewed in Shankar et al., 2005; Stevenson, 2004) . Briefly, the concept has been successfully applied to therapeutic approaches directed against HIV (Berkhout, 2004; Boden et al., 2004; Cullen, 2005) , HCV permissive mosquitoes in order to interrupt Dengue virus transmission (Sanchez-Vargas et al., 2004) . Only mRNA as target Straightforward design and production, relatively inexpensive Effective at low concentration Off-target effects possible Exogenous and endogenous delivery possible Tissue specific expression possible Sequence specific: some discrimination of nucleic acid polymorphisms (SNP) Modified from (Scherer and Rossi, 2003) et al., 2005) , and using RNAi was even suggested as a way to breed non-(reviewed in Chapter 1.3 by Frese and Bartenschlager), SARS-CoV (Wu In most cases RNA interference is efficient and highly specific. However, induction of the interferon system by the Toll-like receptor (TLR) pathway can result from recognition of byproducts of siRNA production or the specific siRNA itself. On the other hand, TLR pathway activation by a given siRNA can be experimentally ruled out in vitro and in vivo in various models, and has not been shown to interfere with the degree or specificity of RNA interference. More difficult to overcome, but possibly less severe, is the interference with off-target cellular RNAs that has been observed sporadically (Jackson et al., 2003; Scacheri et al., 2004) . The potential off-target effects of the respective therapeutic RNA must therefore be studied extensively in the homologous species, e.g. by genome-wide expression analysis. A further aspect is the evaluation of such strategies in vivo: the high sequence specificity of RNA interference will limit the predictive value of any preclinical animal model, since it is not unlikely that a given siRNA will find different off-targets in other host genetic backgrounds. The delivery of the therapeutic principle to the target cell faces similar problems as with other aforementioned techniques that rely on transfer of short nucleic acids or vector-mediated transfer. Synthetic precursor RNAs need to be protected from nucleases and can be delivered using techniques such as liposomes or ligand mediated delivery across the membrane of the target cell. Some cell types can also take up nucleic acids directly. Nevertheless, the effects of synthetic RNA will be transient and short-lived. Sustained as well as regulated intracellular expression of short-hairpin structured siRNA precursors (shRNA) has been achieved by a variety of integrating and non-integrating viral vectors, along with their particular advantages and disadvantages (Tab. 1). Widely used examples are retro-and lentiviral SIN vectors where the shRNA expression cassette is located in the The targeting of infected cells by cytotoxic vectors is conceivable via viral or cellular proteins that are presented exclusively or preferentially at the cell surface. Productive infection with enveloped viruses is usually associated with expression of viral (glyco-)proteins at the surface of cells. Infected cells frequently also show upregulated expression of specific surface molecules such as the MHC-I-like ligands for NK-cell recognition via NKG2D. 3'LTR region; two copies of the shRNA cassette are integrated into the target cell after reverse transcription has duplicated the 3'LTR ( Barton and 2003) ; AAV have also been used (Tomar et al., 2003 ). Medzihitov, 2002 Wiznerowicz and Trono, 2003; Unsurprisingly, viruses have evolved evasion mechanisms (Alcami and Koszinowski, 2000a , 2000c Cerwenka and Lanier, 2003; Lodoen et al., 2004; Krmpotic et al., 2005) . Glycoprotein-deficient rhabdoviruses modified to express CD4, or CD4 plus CXCR4 have been designed as "Magic bullets" for selective infection (Mebatsion et al., 1997; Mebatsion and Conzelmann, 1996) or even killing (Schnell et al., 1997) of cells displaying HIV envelope glycoprotein at their surface. Analogous targeting could be achieved by retroviruses pseudotyped with CD4 or CXCR4 (Endres et al., 1997; Somia et al., 2000) , or anti-CCR5-scFv pseudotyped Sindbis vectors . However, neither strategy has been translated to clinical applications so far. Soluble forms of the main HIV-receptor CD4 can block infection and moreover CD4-TCRζ fusion proteins have been suggested, in which viral binding to the chimeric molecule will conditionally induce cytotoxicity before the virus can establish infection and replicate. Both approaches suffer from the fact that primary isolates are less dependent on CD4 and can infect via alternative receptors. An intracellular variant of CD4 (CD4-KDEL) that is retained in the endoplasmatic reticulum can block viral glycoproteintransport (Buonocore and Rose, 1993) . Intrakines are modified chemokines such as MIP-1α or RANTES designed to be retained in the ER; this results in ER-retention of the HIV coreceptor CCR5, reducing its expression at the cell surface. Mutated forms of viral proteins that can exert trans-dominant negative effects on viral replication have been described for HIV Tat and Rev, and also for Gag, Env, and the protease. Clinical trials with transdominantnegative RevM10 showed increased survival of RevM10-expressing T-cells in AIDS-patients. A strong immune response to the Rev protein was observed, initiating further investigations into Rev-based therapeutic vaccines (Bevec et al., 1992 (Bevec et al., , 1996 . Cellular transport factors such as eIF-5A are required for Rev-mediated nuclear export. Dominant-negative mutants of eIF-5A have been shown to inhibit the replication of HIV, and eIF-5A can also be a target for small molecule inhibitors of hypusine modification (Hauber et al., 2005) . Antibodies or single chain antibodies derived from the variable regions of the immunoglobulin heavy and light chains (intrabodies) have been derived against viral targets such as Env, Tat, Rev, reverse transcriptase, integrase or cellular targets required for efficient HIV-replication. Intrabodies targeting the viral reverse transcriptase and integrase can counteract early in the HIV lifecycle and theoretically can prevent HIV integration and as a result confer immunity from infection. Humanization of the primarily murine monoclonal antibodies will be necessary to decrease the immunogenic potential. Kaposi sarcoma associated herpesvirus (KSHV, HHV8) in lymphoma cells , indicating that such an approach could eventually be used to overcome persistent herpesvirus infections. Gene-directed enzyme prodrug therapy or gene-prodrug activation therapy relates to the transfer and expression of enzymes that metabolize nontoxic prodrugs and convert them into active cytotoxic substances. HSV thymidine kinase (HSV TK), Cytochrome P450, or Cytosinedeaminase from E. coli or other species are the most widely used genes, with many others under consideration. The HIV-LTR is strongly activated by the HIV transactivator protein TAT. Therefore, it has been used in conjunction with marker genes as a sensor to detect replication of HIV (Means et al., 1997) , and for HIV infection-specific gene expression. Conditional expression of TK driven by the HIV-LTR has been shown to confer to infected cells a rather specific susceptibility to Ganciclovir mediated toxicity (Caruso and Bank, 1997; Miyake et al., 2001) . Transfer of TK via a HIV-based lentiviral vector was used to eliminate CD4 tumor cells from adult T-cell leukemia, which is caused by HTLV-I (Obaru et al., 1996) . A further possibility would be conditional expression of a toxin. This approach does not require a prodrug, but it is essential that undesired expression, in the absence of the inducing stimulus, does not occur under any circumstance. Intracellular expression of LANA-specific intrabodies inhibited persistence of Due to the tropism of HIV for cells of the immune system, but also reflecting funding resources, most of T-cell directed vector-and nucleic acid-based antiviral therapies have been aimed at HIV (Gilboa and Smith, 1994) . These have included transfer of antisense oligonucleotides, ribozymes or siRNA targeted at viral sequences or to host factors critical for virus replication, e.g. the HIV coreceptor CCR-5; expression of TAR or REV decoy RNAs; expression of intrabodies directed against TAT, REV; expression of transdominant Rev-mutants such as RevM10, and targeting of HIV-coreceptors (summarized in Rössig and Brenner, 2004) . Stimulation of T-cells for efficient transduction can lead to unwanted increases in HIV replication. Further problems with nucleic-acid based therapies (antisense, RNAi, ribozymes) arise from the high mutation rate and enormous sequence variability of HIV-Quasispecies, which contrasts with the high sequence specificity of e.g. RNAi and ribozymes. It is predictable that resistant HIV-1 variants will arise rapidly in vivo. Selection of conserved sequences in the LTR or within leader sequences may partially avoid this evasion mechanism, as will simultaneously targeting of multiple essential HIV-1 sequences or of targeting essential host genes that do not mutate. RNA decoy requires overexpression of TAR-or RRE-Sequences (e.g. by Pol-III-transcription) but is also less susceptible to sequence variation, since it targets viral proteins. Ribozymes have enzymatic activity and are therefore only needed in smaller amounts than classical antisense strategies, though the natural mechanism of RNAi seems to require even smaller amounts of the therapeutic RNA-molecules (reviewed by Peracchi, 2004) . The success of highly active antiretroviral therapy (HAART) with conventional drugs has largely decreased the demand for such novel therapies as a first line approach; however, there may be a place as a supplement, e.g. for transient salvage therapy to eliminate multi-resistant HIV by RNAi. In the recent years, a valuable addition to conventional tumor therapy has been brought about by specific monoclonal antibodies. These reagents are directed either against antigens preferentially or exclusively expressed on tumors, such as Her2, or in other cases serve to eliminate specific cell populations, that include the tumor cells but also normal cells, such as anti-CD20 (Rituximab). Although responses could not be achieved in all patients with tumors expressing high levels of the respective target antigens, a focus of attention has been created toward targeted therapeutics, to develop alternative and potentially more efficient reagents. Cytotoxic T-cell immunity is central to the control of viral infection. T lymphocytes physiologically recognize antigens through TCR interaction with short peptides presented by MHC class I or II molecules. Activation of naïve T cells depends on professional antigen-presenting cells (APCs) that provide necessary co-stimulatory signals for initial and clonal expansion. Without co-stimulation, unresponsiveness and clonal anergy may be the outcome of TCR activation. Furthermore, virus-specific cytotoxic T-cells can not be derived from immunologically naïve individuals. A variety of techniques to bypass the need for immunization for the generation of immune effector cells with desired recognition specificity have been worked out and will be described below. However, large scale cultivation of (transfected or transduced) T-cells is laborious and technically challenging, as is expansion of virus-specific T-cells when and starting from small number of CTL in the periphery; complex and time consuming protocols for enrichment are necessary to achieve the quantities (~10 7 cells) that are considered to be required for therapy. Adoptive T-cell therapy has been successfully applied to tumors, including EBV-related post-transplant lymphoproliferative disorders (PTLD) (Papadopoulos et al., 1994; Rooney et al., 1995 Rooney et al., , 1998 , and to Cytomegalovirus (CMV)-related disease in immune suppressed transplant recipients (Walter et al., 1995; Peggs et al., 2003; Einsele and Hebart, 2004) . Adoptive transfer of gene-marked tumor and HIV-specific CTL has shown intact homing to sites of HIV-replication and local function, as well as good persistence, although therapeutic benefits were limited (Brodie et al., 1999 (Brodie et al., , 2000 . While effective treatment options exist for EBV-related PTLD in the form of Yttrium-90-Labeled Ibritumomab Tiuxetan radioimmunotherapy or Rituximab Immunotherapy (Jaeger et al., 2005; Milpied et al., 2000) , CMVrelated disease is still highly problematic; CMV reactivation can cause severe morbidity and mortality in immune compromised patients and those allogenic hematopoietic progenitor cell transplantation is at particular risk. In such patients, the recovery of CMV-specific cytotoxic T lymphocytes (CTL) seems to be vital in the reconstitution of CMV specific immunity. constellation of CMV-seronegative donor/CMV-seropositive recipient in with HIV infection, even with appropriate antiviral drug treatment. The Remarkably, beneficial effects were shown for adoptive transfer of Cytolytic effector cells can be genetically modified to carry virus-specific TCR or chimeric receptors based on antibody recognition sites on the surface: Antibody-mediated recognition of viral antigens can thereby be linked with cytolytic effector cells, which then possibly have potential for improved localization, homing and enhanced efficacy. Transfer of tumor-specific TCRα and β-chains (or their specificity determining regions) to effector T-cells has been done in murine models (Kessels et al., 2001 (Kessels et al., , 2005 Willemsen et al., 2003; Tahara et al., 2003) and can probably be also achieved for virus-specific TCRs. Such transferred receptors will recognize processed peptides that can be derived from diverse viral proteins, not restricted to molecules expressed at the cell surface. However, recognition of MHC-presented peptides will depend on the correct HLA background. The formation of heterodimeric TCR consisting of one original and one transferred TCR chain could in theory give rise to new, potentially autoreactive T-cell specificities. Strategies have been developed to specifically target activated T-cells towards infected cells that circumvent MHC-restriction of antigen recognition. The immunoreceptor ("T-body") strategy relies on transfer of cytolytic T-cells that carry an antigen-specific, recombinant receptor with antigen at the cell surface. Construction of chimeric TCR can be done via gene fusion in which a specific extracellular domain derived from a monoclonal antibody is combined with signal transducing components from T-cells. The specific complementarity determining regions (CDR) of the antibodies variable heavy and light chain, i.e. a single-chain antibody fragment (scFv), mediates recognition of target cells. This is coupled via a transmembrane domain to specific signaling domains of T-cell signal transducing molecules such as the TCRζ-chain and the costimulatory molecule CD28 (Abken et al., 2002) . Similar chimeric receptors have been derived from binding domains of natural ligands or antibodies fused directly to the TCRα and TCRβ chains, although this may result in formation of heterodimeric TCR when expressed CMV-specific T cell clones or polyclonal CTL from CMV seropositive donors that were expanded in vitro (reviewed in Einsele and Hebart, 2004) . T-cells can be directed against every cell defined by the particular target signaling properties at their surface. In principle, immunoreceptor grafted on T-lymphocytes. Upon antigen binding, the chimeric receptors generate activating signals in the effector cell similar to those initiated by the TCR complex. Delivery of such recombinant molecules into NK-or T-cells with cytolytic capacity has been shown to direct them toward the target which is specifically recognized by the antibodies CDR. The major advantage of this approach compared to expression of a conventional TCR is that recognition is not restricted to HLA, which would allow preparation, expansion and storage of virus specific cytotoxic cells for use "of-the-shelf". Furthermore, presentation of a peptide by MHC is not required. This is specifically interesting as a number of viruses, including human CMV, are able to downmodulate MHC from the surface of infected cells (Mocarski, Jr., 2004; Hewitt, 2003) . On the other hand, the target molecule has to be presented on the surface of the infected cell (or tumor cell) in a form that is recognizable for the antibody CDR. Processed peptides derived from target molecules that are presented on the MHC are usually not recognized. In initial clinical studies, infusion of such cells into patients proved to be safe and transient therapeutic effects have been observed. Initial HIVdirected clinical trials lacked therapeutic effectiveness and persistence of modified cells in vivo. There are inherent limitations of the immunoreceptor technology: Impaired persistence may result from recognition of the chimeric receptor as foreign, resulting in elimination. Furthermore, T-helper cells are required for efficient CTL function. Impaired signaling capacity that does not achieve the appropriate signal strength in the right context, and lack corresponding costimulatory signals, could also lead to anergy or elimination. Enhanced receptor molecules have therefore been constructed that include functional domains from costimulatory molecules. The promising technique could also be improved by usage of humanized molecules, as well as transduction of cells with specificity against a strong antigen, such as EBV, to improve persistence (summarized in Brenner, 2003, 2004) . Graft versus host disease like effects resulting from autoaggressive behavior of transferred autologous CTL have been observed in other contexts. The altered specificity of T-bodies and heterodimeric TCR can possibly induce autoimmune side effects, though they have not been observed with the relatively small patient numbers treated to date. Lymphoproliferative syndrome can be caused by transduced cells that result from insertion mutagenesis by the vector; this danger might be partially overcome by self-inactivating vectors, by introduction of suicide genes to ablate the unwanted cells, or by gene transfer into mature cells that may be easier to eliminate than stem cells. Possible solutions could be preselection of transferred cells for integration sites, if suitable strategies can be developed. Immunogenicity or undesired behavior of suicide genes could be overcome by novel physiological suicide genes such as CD20 (for elimination by Rituximab, Introna et al., 2000) , or conditional proapoptotic molecules derived from endogenous genes (summarized in Rössig and Brenner, 2004) . Numerous vector-based vaccination and immunity enhancing strategies have been developed, also employing specific gene transfer into professional APC such as Langerhans or dentritic cells (DC) (Jenne et al., 2001) . RNAand DNA-virus-based replicons that are under development for prophylactic and therapeutic vaccination are mostly targeted against HIV, viral hepatitis, HPV-associated cervical cancer (Chapter 2.5 by L. Gissmann), as well as toward more fashionable and recent threats such as SARS-CoV, Filovirus, and those relating to "Biodefense" (Lee et al., 2005) . The reader is referred to recent reviews focusing on Adenovirus- (Tatsis and Ertl, 2004) Alphavirus- (Lundstrom, 2001) , and DNA-vaccine vectors (Srivastava and Liu, 2003; Duenas-Carrera, 2004; Giri et al., 2004) . Vaccines based on Adenoviruses or on gene-modified poxviruses (Drexler et al., 2004; Moss, 1996) , such as modified Vaccinia strain Ankara (MVA), may be specifically considered in situations where adequate medical supply chains and financial resources do not exist. Vaccine formulations based on (lyophilized) DNA are also highly stable under adverse circumstances. The success of Variola elimination did crucially depend on the enormous stability, effectiveness and low cost of the Vaccinia virus. MVA-based vaccination trials showed good safety and immunogenicity of MVA expressing HIV Nef in HIV patients (Harrer et al., 2005) , and there is promising data on regression of precancerous cervical lesions in a preclinical study of MVA expressing HPV E2 (Corona Gutierrez et al., 2004) . The intensified use of genetically modified viruses as gene transfer vectors has to consider a number of potential risk factors and their implications for activities with viral vectors. Specific and careful risk assessment is necessary from the perspective of naturally occurring cross-species transfer of viruses, and of possible host-range mutants resulting either from cell culture (using non-host species cells) or tropism engineering (Louz et al., modified cells may be useful to (transiently) support the host immune system in its struggle with the viral intruder until its own resources have sufficiently recovered. The challenge will be to maintain the balance. Tuning tumorspecific T-cell activation: a matter of costimulation? Cell type-specific targeting with sindbis pseudotyped lentiviral vectors displaying anti-CCR5 single-chain antibodies Viral mechanisms of immune evasion Retroviral delivery of small interfering RNA into primary cells Side effects of retroviral gene transfer into hematopoietic stem cells It remains open if viral vector-based antiviral therapy can be curative in Hum lentiviral vectors for short hairpin RNA delivery into human cells Chance or necessity? Insertional mutagenesis in gene therapy and its consequences No Evidence for Tumorigenesis of AAV Vectors in a Large-Scale Study in Mice RNA interference as an antiviral approach: targeting HIV-1 Inhibition of human immunodeficiency virus type 1 replication in human T cells by retroviral-mediated gene transfer of a dominant-negative Rev trans-activator Inhibition of HIV-1 replication in lymphocytes by mutants of the Rev cofactor eIF-5A HIV-1-specific RNA interference In vivo migration and function of transferred HIV-1-specific cytotoxic T cells HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death The influenza A virus NS1 protein binds small interfering RNAs and suppresses RNA silencing in plants Receptor targeting of adeno-associated virus vectors Blockade of human immunodeficiency virus type 1 production in CD4+ T cells by an intracellular CD4 expressed under control of the viral long terminal repeat Combined DNA vaccines formulated either in DDA or in saline protect cattle from Mycobacterium bovis infection Efficient retroviral gene transfer of a Tat-regulated herpes simplex virus thymidine kinase gene for HIV gene therapy NKG2D ligands: unconventional MHC class I-like molecules exploited by viruses and cancer RNA interference: the silent treatment Gene therapy progress and prospects: episomally maintained self-replicating systems Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus Intrabodies targeting the Kaposi's sarcoma-associated herpesvirus latency antigen inhibit viral persistence in lymphoma cells Molecular genetic analysis of herpesviruses and their potential use as vectors for gene therapy applications Does RNA interference have a future as a treatment for HIV-1 induced disease? Episomal and integrated copies of Epstein-Barr virus coexist in Burkitt lymphoma cell lines Human influenza virus NS1 protein enhances viral pathogenicity and acts as an RNA silencing suppressor in plants Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors Marker gene transfer into human haemopoietic cells using a herpesvirus saimiri-based vector Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential? Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue DNA vaccination against hepatitis C CMV-specific immunotherapy Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells RNA interference is mediated by 21-and 22-nucleotide RNAs Targeting of HIV-and SIV-infected cells by CD4-chemokine receptor pseudotypes Gene therapy for infectious diseases: the AIDS model DNA vaccines against human immunodeficiency virus type 1 in the past decade Targeting HSV amplicon vectors Epstein-Barr virus integration in human lymphomas and lymphoid cell lines Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1 Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption Identification of cellular deoxyhypusine synthase as a novel target for antiretroviral therapy The MHC class I antigen presentation pathway: strategies for viral immune evasion Herpesvirus saimiri pathogenicity enhanced by thymidine kinase of herpes simplex virus Functional long-term thymidine kinase suicide gene expression in human T cells using a herpesvirus saimiri vector Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies Expression profiling reveals off-target gene regulation by RNAi AntiCD20 monoclonal antibody-based radioimmunotherapy of relapsed chemoresistant aggressive posttransplantation B-lymphoproliferative disorder in heart-transplant recipient Viral vectors for dendritic cell-based immunotherapy American Society of Gene Therapy meeting. Retroviral vectors: a doubleedged sword Gene transfer of MHC-restricted receptors Immunotherapy through TCR gene transfer Letter to the editors of Nature from the American Society of Gene Therapy (ASGT) and the European Society of Gene Therapy (ESGT) NK cell activation through the NKG2D ligand MULT-1 is selectively prevented by the glycoprotein encoded by mouse cytomegalovirus gene m145 Viral vectors for use in the development of biodefense vaccines Inhibition of human immunodeficiency virus type 1 replication in primary macrophages by using Tat-or CCR5-specific small interfering RNAs expressed from a lentivirus vector Induction and suppression of RNA silencing by an animal virus Strong host resistance targeted against a viral suppressor of the plant gene silencing defence mechanism Interferon antagonist proteins of influenza and vaccinia viruses are suppressors of RNA silencing Murine leukemia induced by retroviral gene marking Double-stranded RNA-binding proteins could suppress RNA interference-mediated antiviral defences The cytomegalovirus m155 gene product subverts natural killer cell antiviral protection by disruption of H60-NKG2D interactions Cross-species transfer of viruses: implications for the use of viral vectors in biomedical research, gene therapy and as live-virus vaccines Alphavirus vectors for gene therapy applications Improvement of nonviral gene therapy by Epstein-Barr virus (EBV)-based plasmid vectors Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus Specific infection of CD4+ target cells by recombinant rabies virus pseudotypes carrying the HIV-1 envelope spike protein A CXCR4/CD4 pseudotype rhabdovirus that selectively infects HIV-1 envelope protein-expressing cells Adeno-associated virus vectors integrate at chromosome breakage sites Chromosomal effects of adenoassociated virus vector integration Large-scale analysis of adeno-associated virus vector integration sites in normal human Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients Selective killing of human immunodeficiency virus-infected cells by targeted gene transfer and inducible gene 4.3. Vector-based Antiviral Therapy cells Immune escape and exploitation strategies of cytomegaloviruses: impact on and imitation of the major histocompatibility system Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety AAV serotype 2 vectors preferentially integrate into active genes in mice Large-scale molecular characterization of adeno-associated virus vector integration in mouse liver Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo Gene therapy for adult T cell leukemia using human immunodeficiency virus vector carrying the thymidine kinase gene of herpes simplex virus type 1. Hum Herpes simplex virus type 1 amplicons and their hybrid virus partners, EBV, AAV, and retrovirus Office of Biotechnological Activities at NIH and the Recombinant DNA Advisory Committee Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines Prospects for antiviral ribozymes and deoxyribozymes Identification of microRNAs of the herpesvirus family Identification of virus-encoded microRNAs T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virusinduced lymphoma in allogeneic transplant recipients Chimeric T-cell receptors for the targeting of cancer cells Genetic modification of T lymphocytes for adoptive immunotherapy Plant viral suppressors of RNA silencing Cloning and identification of a microRNA cluster within the latency-associated region of Kaposi's sarcoma-associated herpesvirus RNA interference, arthropod-borne viruses, and mosquitoes Targeting retroviral and lentiviral vectors Silencing of a viral RNA silencing suppressor in transgenic plants Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells Approaches for the sequence-specific knockdown of mRNA Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection Genetic fate of recombinant adeno-associated virus vector genomes in muscle The prospect of silencing disease using RNA interference La Crosse virus nonstructural protein NSs counteracts the effects of short interfering RNA Retroviral vector targeting to human immunodeficiency virus type 1-infected cells by receptor pseudotyping Gene vaccines Therapeutic potential of RNA interference SV40-encoded microRNAs regulate viral gene expression and reduce susceptibility to cytotoxic T cells Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates Reconstitution of CD8+ T cells by retroviral transfer of the TCR alpha beta-chain genes isolated from a clonally expanded P815-infiltrating lymphocyte Adenoviruses as vaccine vectors Oncogenesis Following Delivery of a Nonprimate Lentiviral Gene Therapy Vector to Fetal and Neonatal Mice Use of adeno-associated viral vector for delivery of small interfering RNA Targeted mRNA degradation by double-stranded RNA in vitro Surface-engineering of lentiviral vectors Suppression of gene silencing: a general strategy used by diverse DNA and RNA viruses of plants Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor MicroRNA function in animal development Regulated and constitutive expression of anti-inflammatory cytokines by nontransforming herpesvirus saimiri vectors Genetic engineering of T cell specificity for immunotherapy of cancer Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference Inhibition of SARS-CoV replication by siRNA Overcoming immunity to a viral vaccine by DNA priming before vector boosting RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals The author thanks Elke Heck, Florian Full and Frank Wucherpfennig for critical reading of the manuscript and Helmut Fickenscher for a previous compilation of Table 4 .3-1. This work was supported by the Deutsche Forschungsgemeinschaft (SFB466 and 643), the Interdisciplinary Center for Clinical Research (IZKF: Genesis, Diagnostics and Therapy of Inflammation Processes) at the University of Erlangen-Nuremberg and the Wilhelm Sander-Stiftung (2002.033.1).